糖尿病患者与健康人A-PRF中成骨与炎症因子的对比研究

doi:10.12337/zgkqzzxzz.2025.08.007

摘要/Abstract

摘要： 目的比较糖尿病患者和健康人改良富血小板纤维蛋白（A-PRF）中关键成骨生长因子与炎症因子的释放差异。方法按纳排标准分为糖尿病组和健康人组（每组n=8）,分别采集静脉血,离心制备A-PRF膜并孵育后,在15 min、60 min、8 h、1 d、3 d、10 d、14 d和21 d收集析出液,通过酶联免疫吸附实验检测血小板衍生生长因子-BB（PDGF-BB）、血管内皮生长因子（VEGF）、转化生长因子-β（TGF-β）、表皮生长因子（EGF）、肿瘤坏死因子-α（TNF-α）和白细胞介素-6（IL-6）的释放量并进行比较分析。结果（1）糖尿病组A-PRF中PDGF-BB累积释放量始终低于健康人组,且从15 min开始2组差异具有统计学意义（P<0.01）;（2）糖尿病组A-PRF中VEGF累积释放量在1 d至21 d均低于健康人组（P<0.01）;（3）2组A-PRF中的EGF累积释放量差异无统计学意义（P>0.05）;（4）糖尿病组A-PRF中TGF-β累积释放量从1 d开始始终低于健康人组,且差异具有统计学意义（P<0.05）;（5）糖尿病组A-PRF中TNF-α累积释放量从8 h开始始终都高于健康人组（P<0.05）;（6）2组A-PRF中IL-6累积释放量差异无统计学意义（P>0.05）。结论与健康人相比,糖尿病患者A-PRF中成骨关键生长因子PDGF-BB、VEGF、TGF-β累积释放量显著降低,炎症因子TNF-α则持续升高,而EGF与IL-6的总体释放量未见显著差异。

关键词: 改良富血小板纤维蛋白, 糖尿病, 生长因子, 炎症因子, 骨愈合

Abstract: Objective To compare the release kinetics of key osteogenic growth factors and inflammatory cytokines in advanced platelet-rich fibrin (A-PRF) between patients with diabetes mellitus (DM) and healthy populations. Methods Participants meeting the inclusion and exclusion criteria were assigned to either the DM group (n=8) or the healthy control group (n=8). Venous blood was centrifuged to prepare A-PRF membranes, and eluates were collected at 15 min, 60 min, 8 h, 1 d, 3 d, 10 d, 14 d, and 21 d post-incubation. The concentrations of platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), epidermal growth factor (EGF), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) were quantified using enzyme-linked immunosorbent assay (ELISA) and analyzed comparatively. Results (1) Cumulative PDGF-BB release from A-PRF in the DM group was consistently lower than that in healthy controls, with statistically significant differences observed from 15 min onward (P<0.01). (2) VEGF release from A-PRF was significantly reduced in the DM group from day 1 to day 21 compared to controls (P<0.01). (3) No statistically significant difference in cumulative EGF release was observed between the two groups (P>0.05). (4) Cumulative TGF-β release from A-PRF was significantly lower in the DM group from day 1 onward (P<0.05). (5) TNF-α release from A-PRF was significantly higher in the DM group than in healthy controls from 8 h onward (P<0.05). (6) No statistically significant difference in cumulative IL-6 release was observed between the two groups (P>0.05). Conclusion Compared to healthy individuals, DM patients exhibited significantly lower cumulative release of osteogenic growth factors (PDGF-BB, VEGF, TGF-β) from A-PRF and elevated levels of the inflammatory cytokine TNF-α. No significant differences were observed in EGF and IL-6 release.

Key words: Advanced platelet-rich fibrin(A-PRF), Diabetes mellitus, Growth factors, Inflammatory factors, Bone healing

农英娇,黎永薇,陆婵,等. 糖尿病患者与健康人A-PRF中成骨与炎症因子的对比研究[J]. 中国口腔种植学杂志, 2025, 30(4): 370-376. DOI: 10.12337/zgkqzzxzz.2025.08.007

Nong Yingjiao, Li Yongwei, Lu Chan, Deng Hanlin, Tang Jiaqin, Li Shujie, Liang Lihua. Comparative study on the release of osteogenic and inflammatory factors in advanced platelet-rich fibrin between diabetic and healthy populations[J].Chinese Journal of Oral Implantology, 2025, 30(4): 370-376.DOI: 10.12337/zgkqzzxzz.2025.08.007.

参考文献

[1] Meldgaard T, Olesen SS, Farmer AD, et al.Diabetic enteropathy: from molecule to mechanism-based treatment[J]. J Diabetes Res, 2018, 2018:3827301. DOI: 10.1155/2018/3827301.
[2] Abd El-Hameed AM, Eskandrani AA, Salah Abdel-Reheim E, et al. The amelioration effect of antidiabetic agents on cytokine expression in patients with type 2 diabetes mellitus[J]. Saudi Pharm J, 2024, 32(5):102029. DOI: 10.1016/j.jsps.2024.102029.
[3] Bahney CS, Zondervan RL, Allison P, et al.Cellular biology of fracture healing[J]. J Orthop Res, 2019,37(1):35-50. DOI: 10.1002/jor.24170.
[4] 黄李蓉, 冯泽儒, 吴红崑, 等. 富血小板纤维蛋白促进骨再生效果的研究[J]. 中国口腔种植学杂志, 2025, 30(2): 118-126.DOI: 10.12337/zgkqzzxzz.2025.04. 005.
Huang LR, Feng ZR, Wu HK, et al.Effect of platelet-rich fibrin on bone regeneration[J].Chin J Oral Implantol, 2025, 30(2): 118-126. DOI: 10.12337/zgkqzzxzz.2025.04.005.
[5] Bahney CS, Zondervan RL, Allison P, et al.Cellular biology of fracture healing[J]. J Orthop Res, 2019,37(1):35-50. DOI: 10.1002/jor.24227.
[6] Fujioka-Kobayashi M, Miron RJ, Hernandez M, et al.Optimized platelet-rich fibrin with the low-speed concept: growth factor release, biocompatibility, and cellular response[J]. J Periodontol, 2017, 88(1):112-121. DOI: 10.1902/jop.2016.160443.
[7] El Bagdadi K, Kubesch A, Yu X, et al.Reduction of relative centrifugal forces increases growth factor release within solid platelet-rich-fibrin (PRF)-based matrices: a proof of concept of LSCC (low speed centrifugation concept)[J]. Eur J Trauma Emerg Surg, 2019, 45(3):467-479. DOI: 10.1007/s00068-017-0785-7.
[8] Yang S, Li Y, Liu C, et al.Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction[J]. Front Endocrinol (Lausanne), 2022, 13:949535. DOI: 10.3389/fendo.2022.949535.
[9] Wang F, Ye Y, Zhang Z, et al.PDGFR in PDGF-BB/PDGFR signaling pathway does orchestrates osteogenesis in a temporal manner[J]. Research (Wash DC), 2023, 6:0086. DOI: 10.34133/research.0086.
[10] Liu M, Liu Y, Luo F.The role and mechanism of platelet-rich fibrin in alveolar bone regeneration[J]. Biomed Pharmacother, 2023, 168:115795. DOI: 10.1016/j.biopha.2023.115795.
[11] Zhu G, Zhang T, Chen M, et al.Bone physiological microenvironment and healing mechanism: basis for future bone-tissue engineering scaffolds[J]. Bioact Mater, 2021, 6(11):4110-4140. DOI: 10.1016/j.bioactmat.2021.03.043.
[12] Tito C, Masciarelli S, Colotti G, et al.EGF receptor in organ development, tissue homeostasis and regeneration[J]. J Biomed Sci, 2025, 32(1):24. DOI: 10.1186/s12929-025-01119-9.
[13] Wang T, He C.TNF-α and IL-6: the link between immune and bone system[J]. Curr Drug Targets, 2020, 21(3):213-227. DOI: 10.2174/1389450120666190821161259.
[14] Sghaireen MG, Alduraywish AA, Srivastava KC, et al.Comparative evaluation of dental implant failure among healthy and well-controlled diabetic patients-a 3-year retrospective study[J]. Int J Environ Res Public Health, 2020, 17(14):5253. DOI: 10.3390/ijerph17145253.
[15] Maruyama M, Rhee C, Utsunomiya T, et al.Modulation of the inflammatory response and bone healing[J]. Front Endocrinol (Lausanne), 2020, 11:386. DOI: 10.3389/fendo.2020.00386.
[16] Zhang M, Yu W, Niibe K, et al.The effects of platelet-derived growth factor-BB on bone marrow stromal cell-mediated vascularized bone regeneration[J]. Stem Cells Int, 2018, 2018:3272098. DOI: 10.1155/2018/3272098.
[17] Zheng SY, Wan XX, Kambey PA, et al.Therapeutic role of growth factors in treating diabetic wound[J]. World J Diabetes, 2023, 14(4):364-395. DOI: 10.4239/wjd.v14.i4.364.
[18] Tyndall WA, Beam HA, Zarro C, et al.Decreased platelet derived growth factor expression during fracture healing in diabetic animals[J]. Clin Orthop Relat Res, 2003, (408):319-330. DOI: 10.1097/00003086-200303000-00043.
[19] Hicklin DJ, Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J]. J Clin Oncol, 2005,23(5):1011-27. DOI: 10.1200/JCO.2005.06.081.
[20] Hoff P, Maschmeyer P, Gaber T, et al.Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model[J]. Cell Mol Immunol, 2013, 10(2):151-158. DOI: 10.1038/cmi.2012.56.
[21] Liu J, Pan S, Wang X, et al.Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives[J]. Eur J Med Res, 2023, 28(1):553. DOI: 10.1186/s40001-023-01431-w.
[22] Felmeden DC, Spencer CG, Belgore FM, et al.Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management[J]. Am J Hypertens, 2003, 16(1):11-20. DOI: 10.1016/s0895-7061(02)03149-7.
[23] Saukkonen T, Mutt SJ, Jokelainen J, et al.Adipokines and inflammatory markers in elderly subjects with high risk of type 2 diabetes and cardiovascular disease[J]. Sci Rep, 2018, 8(1):12816. DOI: 10.1038/s41598-018-31144-8.
[24] Dandona P, Aljada A, Mohanty P, et al.Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9[J]. Diabetes Care, 2003, 26(12):3310-3314. DOI: 10.2337/diacare.26.12.3310.
[25] Klimontov VV, Mavlianova KR, Orlov NB, et al.Serum cytokines and growth factors in subjects with type 1 diabetes: associations with time in ranges and glucose variability[J]. Biomedicines, 2023, 11(10):2843. DOI: 10.3390/biomedicines11102843.
[26] Tsalamandris S, Antonopoulos AS, Oikonomou E, et al.The role of inflammation in diabetes: current concepts and future perspectives[J]. Eur Cardiol, 2019, 14(1):50-59. DOI: 10.15420/ecr.2018.33.1.
[27] Alavi A, Sibbald RG, Mayer D, et al. Diabetic foot ulcers: part I. pathophysiology and prevention[J]. J Am Acad Dermatol, 2014,70(1):1.e1-e18; quiz 19-20. DOI: 10.1016/j.jaad.2013.06.055.
[28] Okizaki S, Ito Y, Hosono K, et al.Suppressed recruitment of alternatively activated macrophages reduces TGF-β1 and impairs wound healing in streptozotocin-induced diabetic mice[J]. Biomed Pharmacother, 2015,70:317-25. DOI: 10.1016/j.biopha.2014.10.020.
[29] Shapouri-Moghaddam A, Mohammadian S, Vazini H, et al.Macrophage plasticity, polarization, and function in health and disease[J]. J Cell Physiol, 2018,233(9):6425-6440. DOI: 10.1002/jcp.26429.
[30] Liu Y, Zhang Y, Zheng Z, et al.Incorporation of NGR1 promotes bone regeneration of injectable HA/nHAp hydrogels by anti-inflammation regulation via a MAPK/ERK signaling pathway[J]. Front Bioeng Biotechnol, 2022, 10:992961. DOI: 10.3389/fbioe.2022.992961.
[31] Liu C, Jiang D.High glucose-induced LIF suppresses osteoblast differentiation via regulating STAT3/SOCS3 signaling[J]. Cytokine, 2017, 91:132-139. DOI: 10.1016/j.cyto.2016.12.016.
[32] Wu M, Wu S, Chen W, et al.The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease[J]. Cell Res, 2024, 34(2):101-123. DOI: 10.1038/s41422-023-00918-9.
[33] Roohi A, Tabrizi M, Abbasi F, et al.Serum IL-17, IL-23, and TGF-β levels in type 1 and type 2 diabetic patients and age-matched healthy controls[J]. Biomed Res Int, 2014, 2014:718946. DOI: 10.1155/2014/718946.
[34] Li Z, Zhang B, Shang J, et al.Diabetic and nondiabetic BMSC-derived exosomes affect bone regeneration via regulating miR-17-5p/SMAD7 axis[J]. Int Immunopharmacol, 2023, 125(Pt B):111190. DOI: 10.1016/j.intimp.2023.111190.
[35] Willeumier JJ, van der Hoeven NM, Bollen L, et al. Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer[J]. Bone Joint J, 2017, 99-B(4):516-521. DOI: 10.1302/0301-620X.99B4.BJJ-2016-0872.R1.
[36] Lundquist R, Holmstrøm K, Clausen C, et al.Characteristics of an autologous leukocyte and platelet-rich fibrin patch intended for the treatment of recalcitrant wounds[J]. Wound Repair Regen, 2013, 21(1):66-76. DOI: 10.1111/j.1524-475X.2012.00870.x.
[37] Hu F, Wang X, Liang G, et al.Effects of epidermal growth factor and basic fibroblast growth factor on the proliferation and osteogenic and neural differentiation of adipose-derived stem cells[J]. Cell Reprogram, 2013, 15(3):224-232. DOI: 10.1089/cell.2012.0077.
[38] Wang Guoxia,Yang Yu,Zhang Shuai,et al.Beta-carotene regulates the biological activity of EGF in IEC6 cells by alleviating the inflammatory process[J]. Cell Cycle, 2022,21(16):1726-1739. DOI: 10.1080/15384101.2022.2067676.
[39] Jung SM, Kim KW, Yang CW, et al.Cytokine-mediated bone destruction in rheumatoid arthritis[J]. J Immunol Res, 2014, 2014:263625. DOI: 10.1155/2014/263625.
[40] Ping SH, Tian FM, Liu H, et al.Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis[J]. Bosn J Basic Med Sci, 2021,21(3):284-293. DOI: 10.17305/bjbms.2020.5142.